Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a.

Biomed Pharmacother

Department of gastroenterology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450018, China. Electronic address:

Published: December 2018

Increasing evidence suggests the involvement of long non-coding RNAs (lncRNAs) in chemoresistance of cancer treatment. However, their function and molecular mechanisms in gastric cancer chemoresistance are still not well elucidated. In the present study, we investigate the functional role of lncRNA cancer susceptibility candidate 2 (CASC2) in cisplatin (DDP) resistance of gastric cancer and discover the underlying molecular mechanism. Results revealed that CASC2 was decreased in DDP-resistant gastric cancer tissues and cells. Gastric cancer patients with low CASC2 expression levels had a poor prognosis. CASC2 overexpression enhanced DDP sensitivity of BGC823/DDP and SGC7901/DDP cells. Conversely, CASC2 knockdown weakened the response of BGC823 and SGC7901 to DPP. Moreover, CASC2 could function as a miR-19a sponge. miR-19a inhibition could overcome DDP resistance in BGC823/DDP and SGC7901/DDP cells, while miR-19a overexpression led to DDP resistance in BGC823 and SGC7901 cells. Notably, miR-19a overexpression counteracted CASC2 up-regulation-mediated enhancement in DDP sensitivity of BGC823/DDP and SGC7901/DDP cells. On the contrary, the inhibitory effect of CASC2 knockdown on the sensitivity of BGC823 and SGC7901 cells to DDP was reversed by miR-19a inhibition. In summary, CASC2 overexpression overcame DDP resistance in gastric cancer by sponging miR-19a, providing a novel therapeutic target for gastric cancer chemoresistance.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2018.09.181DOI Listing

Publication Analysis

Top Keywords

gastric cancer
28
ddp resistance
16
resistance gastric
12
bgc823/ddp sgc7901/ddp
12
sgc7901/ddp cells
12
bgc823 sgc7901
12
cancer
9
casc2
9
cancer sponging
8
sponging mir-19a
8

Similar Publications

Background: Laparoscopic gastrectomy lacks hand-direct tactile sense and has a limited surgical field compared to laparotomy. Apart from textbook classification, there are anatomical variations in the gastric arteries. Laparoscopic gastrectomy presents technical difficulties and necessitates a more comprehensive comprehension of regional anatomy than open surgical procedures.

View Article and Find Full Text PDF

Gastric cancer, a prevalent malignant tumor worldwide, poses a significant challenge to global health. Despite ongoing advancements in treatment methods, its high incidence and mortality rates remain concerning. Although progress in treating gastric cancer is encouraging, a more critical focus is on enhancing prevention efforts.

View Article and Find Full Text PDF

Nomogram for pre-procedural prediction of lymph node metastasis in patients with submucosal early gastric cancer.

Surg Endosc

January 2025

Department of Gastrointestinal Surgery, Northern Jiangsu People's Hospital, Clinical Teaching Hospital of Medical School, Nanjing University, 98 Nantong West Road, Yangzhou, 225001, Jiangsu, China.

Background: The treatment of early gastric cancer (EGC) is contingent upon the status of lymph node metastasis (LNM). Accurate preoperative prediction of LNM is critical for reducing unnecessary surgeries. This study seeks to evaluate the risk factors for LNM in submucosal EGC and develop a predictive model to optimize therapeutic decision-making.

View Article and Find Full Text PDF

The immune composition of solid tumors is typically inferred from biomarkers, such as histologic and molecular classifications, somatic mutational burden, and PD-L1 expression. However, the extent to which these biomarkers predict the immune landscape in gastric adenocarcinoma-an aggressive cancer often linked to chronic inflammation-remains poorly understood. We leveraged high-dimensional spectral cytometry to generate a comprehensive single-cell immune landscape of tumors, normal tissue, and lymph nodes from patients in the Western Hemisphere with gastric adenocarcinoma.

View Article and Find Full Text PDF

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.

Int J Cancer

January 2025

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.

The majority of patients with advanced esophageal or gastric cancer do not start palliative systemic treatment. To gain insight into the considerations underlying the decision not to start systemic treatment, we analyzed characteristics of patients starting and not starting systemic treatment, reasons for not starting systemic treatment, and receipt of local palliative treatments on a nationwide scale. Patients diagnosed with advanced esophageal or gastric cancer between 2015 and 2021 were included (n = 10,948).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!